dr. kopetz on safety data from beacon crc trial in braf v600e-mutant mcrc
Published 4 years ago • 132 plays • Length 0:54Download video MP4
Download video MP3
Similar videos
-
1:09
dr. kopetz on updated data from beacon crc study in braf v600e–mutant crc
-
1:11
dr. kopetz on the rationale for the beacon crc study in braf v600e-mutant mcrc
-
1:54
dr. kopetz on the rationale and primary endpoints of the beacon crc study in mcrc
-
1:51
dr. eng discusses the beacon crc study in braf-mutated crc
-
1:35
scott kopetz, md, shares updates from the beacon trial in braf-mutant colorectal cancer
-
5:23
what you need to know about colorectal cancer
-
6:23
encorafenib, binimetinib, and cetuximab in braf v600e–mutated colorectal cancer
-
52:36
inflammation part 1 - how our cells clear pathogens? (phagocytosis)
-
6:01
beacon trial: triplet therapy in braf v600e–mutated mcrc
-
1:44
dr. kopetz discusses the treatment of braf-mutant crc
-
1:00
dr. kopetz discusses triplet therapy for braf-mutant crc
-
1:45
breakwater: encorafenib plus cetuximab in patients with braf v600e-mutant mcrc
-
1:18
safety lead-in data for beacon crc trial with triplet biologic regimen in mcrc
-
1:05
dr. nelson on qol data from the beacon crc trial in mcrc
-
1:02
updated survival data from beacon crc lead to more specific questions
-
1:14
dr. kopetz on the importance of molecular testing in crc
-
1:39
dr. kopetz on the significance of tumor sidedness in crc
-
1:38
dr. kopetz on the correlation between tumor sidedness and biomarkers in crc
-
1:59
scott kopetz, md, phd, facp, on the implications of the beacon phase 3 study in braf-mutant mcrc
-
3:42
evidence in braf-mutant crc tumors
-
1:34
dr. kopetz on the biology of right- versus left-sided crc
-
5:04
beacon: encorafenib plus cetuximab with or without binimetinib for braf v600e–mutant metastatic ...